Resources

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, vaccine rollout, testing and PPE provided to services.

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

This fact sheet provides our position on the hospital treatment certification.

This document looks at the improvements to the National Framework for Alcohol, Tobacco and other Drug Treatment. It looks at improving processes for communication, coordination, and collaboration (CCC) between and amongst alcohol and other drug (AOD) treatment funders.

These reports delivered weekly on Fridays, list the percentage of people who have self-identified as Indigenous who have been vaccinated against COVID-19 by local government area (LGA).

These reports list the percentage of people who have been vaccinated against COVID-19 by local government area (LGA).

This report lists the percentage of people who have self identified as Indigenous who have been vaccinated against COVID-19, by SA4. The percentages are further broken down by geographic regions and whether they've had one dose or are fully vaccinated.

These reports list the percentage of people who have been vaccinated against COVID-19 by local government area (LGA).

These data files contains statistical data about Australia's COVID-19 vaccinations.

These presentations contain high-level data about Australia's COVID-19 vaccination rollout program.

This presentation, delivered on 25 January 2023, contains an update to Australia's COVID-19 vaccine rollout.

This data file contains statistical data about Australia's COVID-19 vaccinations.

This suite of materials for the 'Japanese encephalitis virus' campaign encourages Australians to cover up, use insect repellent and use a screen or net.

This poster provides key differences between each COVID-19 vaccine approved for use in Australia as per the Australian Technical Advisory Group on Immunisation (ATAGI) guidelines.

This fact sheet explains the separate funding class for individuals who enter residential care for the purpose of receiving palliative care.

Sponsors and suppliers can use the PLMS to create, edit and monitor applications for prostheses listings.

A collection of weekly infographics that provide a traffic light report of the coronavirus (COVID-19) situation across Australia.

This infographic issued on 27 January 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

A collection of resources for health professionals to help people with Gaucher disease (type 1) access the following drugs under the Life Saving Drugs Program: imiglucerase (Cerezyme®), velaglucerase (VPRIV®), and taliglucerase (Elelyso®).

A collection of resources for health professionals to help people with mucopolysaccharidosis type II (MPS II) access idursulfase (Elaprase®) under the Life Saving Drugs Program.

A collection of resources for health professionals to help people with Pompe disease access alglucosidase alfa (Myozyme®) and avalglucosidase alfa (Nexviazyme®) under the Life Saving Drugs Program.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.